Mizuho analyst Uy Ear raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $37 from $32 and keeps an Outperform rating on the shares. With one month remaining in Q4, Zoryve prescription trends have been stronger than expected, the analyst tells investors in a research note. The firm upped its Q4 sales estimate to $113M, above the $110M consensus, and 2026 estimate to $470M, above the $467M consensus. Mizuho also has greater confidence in the potential of Zoryve to convert the steroidal market.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVE
- Arcutis Biotherapeutics completes enrollment in INTEGUMENT-INFANT Phase 2 study
- Arcutis Biotherapeutics announces data from Phase 2 study of ZORYVE published
- Arcutis partners with Tori Spelling, Stella McDermott for campaign
- Arcutis Biotherapeutics announces commercial launch of ZORYVE cream